Skip to main content
. 2020 Jul 19;9(7):2293. doi: 10.3390/jcm9072293

Figure 1.

Figure 1

Three-D model representation for the effect of bone morphogenetic protein (BMP)2 on ARPE-19 barrier functionality. By using a real-time monitoring of transepithelial electric resistance (TER) as an indicator of barrier integrity, BMP2-treatment was initiated after ARPE-19 cells formed confluent mature monolayersindicated by the plateau in TER, y-axis shown in the representative 3D model. Thereafter, monolayers of ARPE-19 cells were treated with BMP2 at different concentrations (0, 25, 50, 100, 200, or 400 ng/mL; (A–F), respectively) and the barrier integrity was monitored over a 100-h period (represented on the z-axis) as well as across 9 frequencies (250, 500, 1000, 2000, 4000, 8000, 16,000, 32,000, and 64,000 Hz, represented as log values on the x-axis). As shown in (A–F), BMP2 did not affect the barrier integrity of ARPE-19 at any of tested concentration compared to the positive control cells, which were treated with TNFα at 100ng/mL (G); n = 4–6.